PDCD1 and lung carcinoma: In the course of processing lung cancer with pembrolizumab, the mediastinal tumor enlarged extremely rapidly from 5 cm to 15 cm in size within 3 months.[12] Therefore, patients with PD-L1 over-expression may potentially benefit from PD-1 inhibitors.